Baudax Bio, Inc. (BXRX) Stock

About Baudax Bio, Inc.

Baudax Bio, Inc. is a pharmaceutical enterprise dedicated to creating and marketing therapeutic solutions for inpatient and urgent care environments. Their flagship commercial offering is ANJESO, an injectable meloxicam formulation designed to alleviate moderate to severe pain, which can be administered independently or in conjunction with non-NSAID pain medications. The company's research and development portfolio features several candidates: BX1000, an intermediate-acting neuromuscular blocker currently in Phase II trials; BX2000, an ultra-short-acting variant of the same class, undergoing Phase I investigation; BX3000, an agent intended to reverse neuromuscular blockade; and Dex-IN, a unique intranasal delivery system for dexmedetomidine. Founded in 2019, the firm operates from its base in Malvern, Pennsylvania.

the stock is valued at a price-to-earnings (P/E) ratio of 0.00, price-to-book of 0.00, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $0.01 and $3.47, and currently trades 99.4% below its 52-week high.

On profitability, Baudax Bio, Inc. generates a return on equity (ROE) of 245.83% — well above the market average, a sign of a high-quality business, return on capital employed of 312.77%, an operating margin of -3600.00%, a net profit margin of -5900.00%.

Official website: www.baudaxbio.com